Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel
Research conducted on osteoarthritis in cats
Study aims to improve diagnosis and treatment

Researchers at the University of Montreal's Quebec Research Group in Animal Pharmacology have attempted to better the ability to diagnose and treat osteoarthritis in cats.

"Osteoarthritis frequently affects cats' elbows, backs and hips and joints in the hind limbs, and its prevalence increases dramatically with age," said lead author Eric Troncy of the university's Faculty of Veterinary Medicine. He added that despite the prevalence of the condition, improvements are needed in its diagnosis and treatment.

"We used our knowledge of cat behaviour and worked with experts in human osteoarthritis to develop a diagnosis tool and test an effective medication: meloxicam."

During the study 120 cats were examined by researchers, 39 of which were believed to be suffering from osteoarthritis. In order to evaluate the pain levels of the 39 sufferers, researchers measured their kinetic gait analysis - which reveals impairments in the limbs, their daily activity as recorded by an accelerometer, and their sensitivity to touch - measured by testing the level of pressure required for the cat to withdraw its paw.

For 74 days, a placebo was administered to a control group, while the remaining animals were given different doses of meloxicam, an anti-inflammatory drug already used in the treatment of other animals. According to researchers, no side effects were experienced, and the drug provided varying levels of pain relief depending on the dosage given.  Professor Troncy said: "Cats that were treated with the high dosage continued to enjoy pain relief for five weeks after dosage stopped."

The drug however, did not appear to reduce pain associated with touch, such as stroking. The same flaw, according to researchers, occurs in hypersensitive osteoarthritic humans who are being treated with anti-inflammatory drugs. Despite this, Troncy added: "The development of adapted therapy protocols to correctly treat arthritis associated with chronic pain will provide a better quality of life particularly in older cats and will in turn have a direct impact on owners, as their cat will be more active and sociable."

Researchers are now looking at how brain scans could further improve our understanding of pain in cats, particularly with regard to the neurophysiological hypersensitive process. Meloxicam is to be considered for use in cats by the Europe Medicines Agency in April of this year.

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.